CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model
Jin Hee Kim, Gha Young Lee, Hyo Jin Maeng, Hoyoun Kim, Jae Hyun Bae, Kyoung Min Kim, Soo Lim
Endocrinol Metab. 2021;36(1):157-170.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.781

Excel Download

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model
Jin Hee Kim, Gha Young Lee, Hyo Jin Maeng, Hoyoun Kim, Jae Hyun Bae, Kyoung Min Kim, Soo Lim
Endocrinology and Metabolism. 2021;36(1):157-170   Crossref logo
Link1 Link2 Link3
Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes
Jang Won Son
Endocrinology and Metabolism. 2021;36(1):57-59   Crossref logo
Link1 Link2 Link3
Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor–Deficient Mice
Bilal A. Omar, Birgitte Andersen, Jacob Hald, Kirsten Raun, Erica Nishimura, Bo Ahrén
Diabetes. 2013;63(1):101-110   Crossref logo
Link1 Link2
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes
Christophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal
Diabetes, Obesity and Metabolism. 2022;24(5):788-805   Crossref logo
Link1 Link2 Link3
Effects of body weight reduction on plasma fibroblast growth factor 21 in obese patients with type 1 diabetes mellitus
F. Musil, V. Blaha, A. Ticha, R. Hyspler, M. Haluzik, J. Lesna, A. Smahelova, L. Sobotka
Atherosclerosis. 2015;241(1):e178-e179   Crossref logo
Link1 Link2
Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
SASAN FAZELI, NICOLE EHRHARDT
Diabetes. 2018;67(Supplement_1):   Crossref logo
Link1 Link2
Fibroblast growth factor 21 serum concentrations in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2).
M. Walus-miarka, B. Idzior-Walus, M. Kapusta, A. Trojak, P. Miarka, M.T. Malecki
Atherosclerosis. 2018;275:e151   Crossref logo
Link1 Link2
Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of Type 2 diabetes
J. Rachman
Diabetic Medicine. 2004;21(s1):18-20   Crossref logo
Link1 Link2
Serum Fibroblast Growth Factor-21 Is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Incident Atherosclerotic Cardiovascular Diseases
LIANG WU, LINGLING QIAN, HUATING LI, WEIPING JIA
Diabetes. 2018;67(Supplement_1):   Crossref logo
Link1 Link2
Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
Nina A. Petunina, Milena Е. Telnova
Diabetes mellitus. 2018;21(4):293-300   Crossref logo
Link1 Link2